Published Date: 02 Mar 2023
Vaccination against SARS-CoV-2, the virus that causes COVID-19, can reduce the severity and duration of COVID in people who have persistent symptoms after infection, he said.
Read Full NewsImproving Diabetic Macular Edema Care in Native American Communities: Real-World Insights and Culturally Responsive Approaches
Targeting the PI3K/AKT/PTEN Pathway to Optimize Treatment for HR+/HER2- Breast Cancer
Navigating Treatment-Associated Adverse Events and Patient-Centered Supportive Care in HR+/HER2- Breast Cancer
Optimizing Safe Administration of Novel Infusion Therapies in HR+/HER2- Advanced Breast Cancer
Optimizing Treatment Sequencing in Endocrine-Refractory HR+/HER2- Breast Cancer
Evaluating the Latest Evidence on Emerging Somatostatin Receptor Ligands for Acromegaly
Navigating Advances in Cystic Fibrosis Care
1.
Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.
2.
A study has developed molecular markers that predict meningioma recurrence.
3.
First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.
4.
Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.
5.
A large study found that monolayers were superior in detecting cancer.
1.
Precision Oncology: Cancer Screening, Genetic Counseling & Hereditary Cancer Syndromes Integration
2.
Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches
3.
Debunking Myths About Systemic Mastocytosis: Separating Fact from Fiction
4.
Unlocking the Potential of Etoposide: A Novel Approach to Cancer Treatment
5.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
2.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
3.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
5.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation